Small- and mid-sized biotechs can avoid the “big pharma trap” as they scale from R&D to commercialisation by building proportionate, risk-based compliance frameworks. Some biotechs overcorrect by copying large-company SOPs, adding bureaucracy, and implementing global-style frameworks that don’t match their size/stage of development. This leads to frustration and workarounds .
Regulators do not expect small biotechs to mirror “big pharma”. All biotech and pharma companies, whatever their size operate under the same regulatory framework. Organisations are expected to demonstrate evidence of proportionate control, accountability, and risk awareness, aligned to their size, activities, and stage of development.
The goal isn’t to “become big pharma,” but to become commercially ready; ready for scrutiny, growth, and accountability, using a pragmatic, maturity-led approach.

Many biotech organisations assume the transition from R&D to commercial is gradual, but in reality it represents a step change in healthcare compliance expectations. Codes such as ABPI, EFPIA, IFPMA and PhRMA apply well before product launch, with obligations triggered by pre‑commercial and market‑facing activity rather than organisational maturity. This article explores the key compliance risks that face R&D‑led organisations as they transition to commercial, including scientific exchange, HCP interactions, patient engagement and transparency, and explains what “commercial‑ready compliance” really looks like for biotechs preparing for their first launch.

In the pharmaceutical sector, social media activity by employees can carry significant compliance risks. This article outlines key dos and don’ts, including the dangers of reposting promotional content, engaging with third-party posts, and discussing prescription-only medicines online. With global regulations in mind, it introduces a simple framework, Restrict, Report, Regionalise, to help employees navigate digital platforms responsibly and protect both personal and organisational integrity.